PTP4A3 and rhabdomyosarcoma: Together, the preclinical evidence indicated PRL3 to be a prevalent and specific cancer target in childhood tumors, which supported the compassionate first-in-child use of PRL3-zumab in a pediatric patient with multiply recurrent rhabdomyosarcoma.